SCHEMBL3770307

SCHEMBL3770307

CC(=NO)c1cc2cccc(F)c2nc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
MGLL Q99685 1/20 0.38
LMNA P02545 3/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
GFER P55789 2/20 0.35
POLB P06746 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
ALDH2 P05091 1/20 0.34
ALDH1A3 P47895 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770305 1.00 ESR1 (0.38) ESR1ESR2MGLLLMNAMAPT
SCHEMBL2717594 1.00 ESR1 (0.38) ESR1ESR2MGLLLMNAMAPT
SCHEMBL2719330 0.81 SMN1; SMN2 (0.52) LMNAMAPTALDH1A1GFERPOLB
SCHEMBL14815892 0.78 ESR1 (0.37) ESR1ESR2MGLLLMNAMAPT
SCHEMBL14815893 0.78 ESR1 (0.37) ESR1ESR2MGLLLMNAMAPT
SCHEMBL1695203 0.78 ESR1 (0.37) ESR1ESR2MGLLLMNAMAPT
SCHEMBL13017492 0.74 ALDH1A1 (0.53) LMNAMAPTALDH1A1GFERSMN1; SMN2
SCHEMBL13684949 0.74 KDM4E (0.52) LMNAMAPTALDH1A1KMT2AMEN1
SCHEMBL29768864 0.73 MBNL1 (0.42) LMNAALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL29768837 0.73 MBNL1 (0.42) LMNAALDH1A1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873704-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed
US-20160333017-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2016-11-17 US disclosed
EP-2445900-B1 POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES AMGEN INC (US) 2016-03-02 EP disclosed
US-20100331306-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331306-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 ESR1 1059/4885ESR2 602/4885MGLL 860/4885
US-20160333017-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 ESR1 1068/4885ESR2 595/4885MGLL 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.